The LATi 2017 LifeSciences Showcase is a mini-exhibition, followed by a conference to be held at Nottingham Trent University Clifton Campus, hosted by the NTU School of Science and Technology.
The theme of the LATi 2017 LifeSciences Showcase is the 'Commercial Realities of Personalised Healthcare’, looking at the why personalised medicine has become such a hot topic, the realities of developing commercially viable products and services, and the opportunities for life sciences SMEs.
The LATi 2017 LifeSciences Showcase is a unique and focused networking event for people that work in the lifesciences, bioscience, pharma and drug discovery.
15:45 – Registration for conference
16:00 to 18:00 – Talks in New Lecture Theatre
16:00 – Welcome from Dean of NTU School of Science & Technology
16:05 – Dr Alasdair Gaw (MC)
16:10 – Dr Kath Mackay, Head of Precision and Discovery Medicine, Innovate UK
16:35 – Aamir Butt, CEO Tumour Trace
17:00 – Prof Graham Pockley, Director of John van Geest Cancer Research Centre
17:25 – Dr Alasdair Gaw
17:50 – Q&A
18:00 – Close
______________________________________
+ Nemaura Pharma
+ Xenogesis
+ Access Science Jobs
+ TouchApp
+ Veolia Water Technologies
+ Datalink Electronics
+ Adamson Jones
+ TBAT Innovation
+ Potter Clarkson
+ Hallam Internet
+ Medilink East Midlands
+ Charnwood Borough Council
+ Department for International Trade
+ NTU Working with You
+ NTU School of Science and Technology
_______________________________________
Alasdair has worked on several international consortia including COPD-Gene, UBIOPRED, COPD Biomarker Qualification Consortium and COPD-MAP consortium to improve patient phenotyping and disease characterisation.
Dr Kath Mackay is Head of Precision and Discovery Medicine at Innovate UK and leads a team delivering programmes in precision medicine, drug discovery, digital health and disease prevention & wellbeing. Innovate UK is the UK’s innovation agency, a non-departmental public body which is the prime channel through which the Government incentivises innovation in business.
Kath has over 15 years experience in commercial business development and marketing, and life sciences research, spanning multiple disease areas and technologies. Most recently, Kath was Business Development Director at Epistem Plc, where she established the business development platform for their service business in the USA, leading a team to initiate new projects to develop therapeutics and companion biomarkers for regenerative medicine, oncology and inflammation.
Kath holds a PhD in Pharmacology and BSc in Pharmacology & Physiology from the University of Manchester.
Aamir Butt, CEO of Tumour Trace has 20-years experience of starting and selling his own businesses, and supporting over 90 other businesses, taking new products to new markets is at the heart of his expertise. Aamir has built scalable business models across several verticals including health, medtech, digital and service industries.
Tumour Trace develop innovative, patented cancer screening and diagnostic technology. Based on peer review research their in-vitro portable screening device has been validated following proof of concepts in the UK, Serbia and India. The company’s vision is to enable screening covering all cancers to be available to everyone, everywhere.
Professor Graham Pockley, Director of the John van Geest Cancer Research Centre, obtained a Doctor of Philosophy for studies investigating the immunomodulatory properties of human placental protein 14 from Sheffield City Polytechnic (now Sheffield Hallam University) in 1988. He then undertook a 2-year postdoctoral fellowship studying ocular mucosal immunoregulation in the Department of Immunology and Microbiology at Wayne State University, Detroit, USA.
In 1990, he returned to the UK to take up a Lectureship and direct the experimental transplantation programme in the Professorial Surgical Unit at the Medical College of St. Bartholomew´s Hospital, London. He returned to Sheffield as a Lecturer in 1994, and was promoted to Reader in Immunobiology in 1996 and Professor of Immunobiology in 2004.
Professor Pockley, who was appointed Director of the John van Geest Cancer Research Centre in September 2016, has a number of responsibilities relating to its administration and the management of its research programme.Further information : www.lati.org.uk
The theme of the LATi 2017 LifeSciences Showcase is the 'Commercial Realities of Personalised Healthcare’, looking at the why personalised medicine has become such a hot topic, the realities of developing commercially viable products and services, and the opportunities for life sciences SMEs.
The LATi 2017 LifeSciences Showcase is a unique and focused networking event for people that work in the lifesciences, bioscience, pharma and drug discovery.
- Hear about the innovative research and development projects undertaken in the life sciences sector
- Learn from experts in the industry about how to profit from research and innovation
- Network with key players in the industry
Outline Agenda
13:30 – 15:30 Exhibition in NTU Pavilion15:45 – Registration for conference
16:00 to 18:00 – Talks in New Lecture Theatre
16:00 – Welcome from Dean of NTU School of Science & Technology
16:05 – Dr Alasdair Gaw (MC)
16:10 – Dr Kath Mackay, Head of Precision and Discovery Medicine, Innovate UK
16:35 – Aamir Butt, CEO Tumour Trace
17:00 – Prof Graham Pockley, Director of John van Geest Cancer Research Centre
17:25 – Dr Alasdair Gaw
17:50 – Q&A
18:00 – Close
______________________________________
Exhibitors
An exhibition will be held in “The Pavilion” before the conference, with local life sciences enterprises showcasing their work, including:+ Nemaura Pharma
+ Xenogesis
+ Access Science Jobs
+ TouchApp
+ Veolia Water Technologies
+ Datalink Electronics
+ Adamson Jones
+ TBAT Innovation
+ Potter Clarkson
+ Hallam Internet
+ Medilink East Midlands
+ Charnwood Borough Council
+ Department for International Trade
+ NTU Working with You
+ NTU School of Science and Technology
_______________________________________
Speakers
Alasdair Gaw has over 25 years experience in the Pharmaceutical industry in the UK and Sweden, covering senior leadership across a variety of therapeutic areas, delivering several projects to positive clinical studies, including Director of Translational Medicine at AstraZeneca and a health care specialist role for the Stratified Medicine Innovation Platform of Innovate UK.Alasdair has worked on several international consortia including COPD-Gene, UBIOPRED, COPD Biomarker Qualification Consortium and COPD-MAP consortium to improve patient phenotyping and disease characterisation.
Dr Kath Mackay is Head of Precision and Discovery Medicine at Innovate UK and leads a team delivering programmes in precision medicine, drug discovery, digital health and disease prevention & wellbeing. Innovate UK is the UK’s innovation agency, a non-departmental public body which is the prime channel through which the Government incentivises innovation in business.
Kath has over 15 years experience in commercial business development and marketing, and life sciences research, spanning multiple disease areas and technologies. Most recently, Kath was Business Development Director at Epistem Plc, where she established the business development platform for their service business in the USA, leading a team to initiate new projects to develop therapeutics and companion biomarkers for regenerative medicine, oncology and inflammation.
Kath holds a PhD in Pharmacology and BSc in Pharmacology & Physiology from the University of Manchester.
Aamir Butt, CEO of Tumour Trace has 20-years experience of starting and selling his own businesses, and supporting over 90 other businesses, taking new products to new markets is at the heart of his expertise. Aamir has built scalable business models across several verticals including health, medtech, digital and service industries.
Tumour Trace develop innovative, patented cancer screening and diagnostic technology. Based on peer review research their in-vitro portable screening device has been validated following proof of concepts in the UK, Serbia and India. The company’s vision is to enable screening covering all cancers to be available to everyone, everywhere.
Professor Graham Pockley, Director of the John van Geest Cancer Research Centre, obtained a Doctor of Philosophy for studies investigating the immunomodulatory properties of human placental protein 14 from Sheffield City Polytechnic (now Sheffield Hallam University) in 1988. He then undertook a 2-year postdoctoral fellowship studying ocular mucosal immunoregulation in the Department of Immunology and Microbiology at Wayne State University, Detroit, USA.
In 1990, he returned to the UK to take up a Lectureship and direct the experimental transplantation programme in the Professorial Surgical Unit at the Medical College of St. Bartholomew´s Hospital, London. He returned to Sheffield as a Lecturer in 1994, and was promoted to Reader in Immunobiology in 1996 and Professor of Immunobiology in 2004.
Professor Pockley, who was appointed Director of the John van Geest Cancer Research Centre in September 2016, has a number of responsibilities relating to its administration and the management of its research programme.
